Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization.
Yufang BiEleanor WheelerMaik PietznerTill F M AndlauerMichelle S YauApril E HartleyBen Michael BrumptonHumaira RasheedJohn P KempMonika FryszJamie RobinsonSjur ReppeVid PrijateljKaare M GautvikLouise FalkWinfried MaerzIngrid GergeiPatricia A PeyserMaryam KavousiPaul S de VriesClint L MillerMaxime BosSander W van der LaanRajeev MalhotraMarkus HerrmannHubert ScharnaglMarcus KleberGeorge DedoussisEleftheria ZegginiMaria NethanderClaes OhlssonMattias LorentzonNick WarehamClaudia LangenbergMichael V HolmesGeorge Davey SmithJonathan H TobiasPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
This study provides genetic evidence to suggest that lower levels of sclerostin may increase risk of hypertension, T2DM, MI, and extent of CAC, and lead to an atherogenic lipid profile. Taken together, these findings underscore the requirement for strategies to mitigate potential adverse effects of romosozumab treatment on atherosclerosis and its related risk factors.